Here, we present a protocol to generate insulin expressing 3D murine pancreatoids from free-floating e10.5 dissociated pancreatic progenitors and the associated mesenchyme.
The pancreas is a complex organ composed of many different cell types that work together to regulate blood glucose homeostasis and digestion. These cell types include enzyme-secreting acinar cells, an arborized ductal system responsible for the transportation of enzymes to the gut, and hormone-producing endocrine cells.
Endocrine beta-cells are the sole cell type in the body that produce insulin to lower blood glucose levels. Diabetes, a disease characterized by a loss or the dysfunction of beta-cells, is reaching epidemic proportions. Thus, it is essential to establish protocols to investigate beta-cell development that can be used for screening purposes to derive the drug and cell-based therapeutics. While the experimental investigation of mouse development is essential, in vivo studies are laborious and time-consuming. Cultured cells provide a more convenient platform for screening; however, they are unable to maintain the cellular diversity, architectural organization, and cellular interactions found in vivo. Thus, it is essential to develop new tools to investigate pancreatic organogenesis and physiology.
Pancreatic epithelial cells develop in the close association with mesenchyme from the onset of organogenesis as cells organize and differentiate into the complex, physiologically competent adult organ. The pancreatic mesenchyme provides important signals for the endocrine development, many of which are not well understood yet, thus difficult to recapitulate during the in vitro culture. Here, we describe a protocol to culture three-dimensional, cellular complex mouse organoids that retain mesenchyme, termed pancreatoids. The e10.5 murine pancreatic bud is dissected, dissociated, and cultured in a scaffold-free environment. These floating cells self-assemble with mesenchyme enveloping the developing pancreatoid and a robust number of endocrine beta-cells developing along with the acinar and the duct cells. This system can be used to study the cell fate determination, structural organization, and morphogenesis, cell-cell interactions during organogenesis, or for the drug, small molecule, or genetic screening.
Delineating the mechanisms of the normal development and the physiology is paramount to understand disease etiology and ultimately cultivate treatment methods. While culturing and differentiating stem cells enables quick and high-throughput analysis of development, it is limited by the existing body of knowledge regarding mechanisms regulating cell fate and artificially recapitulates development in a relatively homogenous, two-dimensional state1,2. Not only is in vivo development affected by extrinsic influences, with different cell types in the niche and milieu providing paracrine signals and organizational support to guide organogenesis, but the function of these cells also relies on their surroundings for guidance3,4,5. Given the importance of these external cues, the limitations of differentiation protocols, and the laborious nature of in vivo mouse models, new systems are needed to experimentally investigate basic developmental processes and physiology.
The emergence of protocols to generate three-dimensional, complex organoids provides a convenient and congruent system to study organogenesis, physiology, drug efficacy, and even pathogenesis. Establishing murine organoids for different systems such as the stomach6 and intestine7 have expanded our understanding of organogenesis, providing a tool to study developmental complexities with fewer restrictions than in vivo and in vitro models. Due to these advances in the murine organoid formation and the advent of human pluripotent stem cells, human intestinal8, retinal9, renal10,11, and cerebral12 organoids have been produced, and this repertoire is only limited by the existing knowledge regarding mechanisms of development.
Of particular interest is the generation of pancreatic organoids, as a myriad of diseases plagues different pancreatic cell types, including acinar cells and ducts in exocrine pancreatic insufficiency13, acinar cells in pancreatitis14, and beta cells in diabetes15. Gaining knowledge regarding the development of these different cell types could aid in understanding their pathology and can, also, act as a platform for personalized drug screening or transplantation. Previously, Greggio et al. developed a method to create murine pancreatic organoids that recapitulate in vivo morphogenesis and develop organized, three-dimensional, complex structures composed of all major pancreatic epithelial cell types16,17. This is a major step forward in the pancreatic field, especially as making cells in vitro can enable biological investigation of beta-cell development. However, a scarcity of endocrine cells formed in this protocol unless the organoids were transplanted into tissue, where the niche could interact and provide instructional cues17. The mesenchyme constitutes the largest portion of the niche, heavily enveloping the developing epithelium from early stages of organogenesis to later stages including endocrine delamination and differentiation3,4,18. The interaction of the mesenchyme with the developing pancreas is yet another example of extrinsic signaling and the importance of maintaining in vivo cellular complexity to study organogenesis.
Here, we describe how to generate three-dimensional pancreatic organoids, termed pancreatoids, from dissociated e10.5 murine pancreatic progenitors. These pancreatoids retain native mesenchyme, self-assemble in free-floating conditions, and generate all major pancreatic cell types, including a robust number of endocrine beta cells19. This approach is best suited for the analysis of endocrine development, as previous protocols lack robust endocrine differentiation. However, using the protocol for pancreatic organoids as described by Greggio et al. is better suited for analysis of pancreatic epithelial branching and morphogenesis, as branching is more limited in pancreatoids.
All animal experiments described in this method were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine.
1. Preparation of Mouse Embryonic Day 10.5 Pancreatic Progenitors
Note: This protocol does not need to be followed under sterile conditions until step 2, however it is optimal to sterilize dissection tools and spray with 70% ethanol prior to use.
2. Culturing Dissociated Progenitors to Form Pancreatoids
Note: The following should be performed in a sterile atmosphere in a standard tissue culture hood, using standard sterile procedures.
3. Processing Pancreatoids for Immunofluorescent Imaging
4. Isolation of RNA from Pancreatoids for Transcript Analysis
Careful dissection of mouse embryos at e10.5 from the uterine horn should yield undamaged embryos in PBS for further dissection (Figure 1A). The gastrointestinal tract can be efficiently removed from the embryo (Figure 1B), permitting discernment of the dorsal pancreatic bud at the junction of the intestine and stomach (Figure 1C-F). The e10.5 pancreatic bud has previously been characterized; progenitors should express Pdx1, Sox9, Ptf1a, and Hes120,21,22,23. Following tissue processing steps, dissociated pancreatic single cells or small groups of cells can be visualized by light microscopy (Figure 1G-H).
In organogenesis media, these free-floating, scaffold-free cells self-assemble and organize into three-dimensional pancreatoids that grow and persist for at least ten days in culture (Figure 2A). The pancreatoids have morphological similarities to the in vivo pancreas, with branching morphogenesis occurring. Using transgenic mice, different cell types or processes can be monitored in real time. For example, using Ins1-eGFP24 mice to mark the formation of endocrine beta cells, pancreatoids can be imaged in daily to visualize beta cell development (Figure 2B). Further, by altering culture conditions, adding small molecules, drugs, or manipulating the genome, not only can the cell fate determination be assessed but changes in structure and morphology can also be investigated. Here we show the application of protein kinase C activator phorbol 12-myristate 13-acetate (PMA) at high concentrations (160 nM), which alters the morphology of developing pancreatoids, leading to loosely associated epithelial cells and increased branching19 (Figure 2C).
To assess the association of pancreatic mesenchyme tissue with pancreatic epithelial cells, immunostaining can be performed for markers of each tissue. Immunostaining of duct marker, DBA25,26, with an endocrine marker, Chga27, and nuclei marked by DAPI reveal multi-lineage formation in pancreatoids (Figure 3A). A mesenchyme marker, Vimentin, co-stained with a pancreatic progenitor marker (from e9.0 to approximately e15.5) Pdx1, shows that the mesenchyme envelops the pancreatoid (Figure 3B). Immunostaining can also be used to examine morphology, with Pdx1 revealing branching structures, as well as different markers of cell types of interest. In Figure 3C, we visualize beta cell development by staining for the epithelial marker Pdx1 and the beta cell marker Ins. Using qPCR analysis, transcripts of progenitors and differentiating cells an be assessed, such as progenitor genes Pdx1 and Hes1, and differentiated markers Prss1, Prss3, Hnf6, Isl1, Nkx6-1, and Ins1 (Figure 4).
Figure 1: Outline of dissection, dissociation, and plating of e10.5 pancreatic progenitors for the pancreatoid generation. (A) The brightfield image of e10.5 embryo. (B) The schematic of dissection procedure, starting at the top left. The red, dashed lines indicate regions to cut, while the green region is the gastrointestinal tract. First, the head is removed followed by the removal of forelimb buds and the opening of the side of the organism. (C) The gastrointestinal tract is carefully removed, with the heart and liver buds protruding from the ventral region of the tract. The stomach, dorsal pancreatic bud, and intestine can be visualized, as shown in the brightfield image. (D) Removal of the heart and liver buds. Schematic is on the left and the brightfield image is on the right. (E) Pinching of the tissue around the dorsal pancreatic bud to expose the bud for dissection. Schematic is on the left and the brightfield image is on the right. (F) The gastrointestinal tract with the dorsal pancreatic bud under brightfield microscopy. In the image on the left, the bend in the intestine is visible, where forceps can be placed when detaching the gastrointestinal tract from the spinal region. On the right, the high magnification brightfield image shows both the dorsal and ventral pancreatic buds. (G) Removal of the dorsal pancreatic bud and processing of tissue before dissociation, resuspension in organogenesis media, and plating. (H) the brightfield image shows dissociated cells immediately after plating. Please click here to view a larger version of this figure.
Figure 2: Monitoring pancreatoids over time. (A) Brightfield images of pancreatoids at day 1, day 2, and day 3. Scale bars=100 um. (B) Manipulation of culture conditions to investigate pancreatic morphogenesis. Here, the addition of high levels of PMA leads to loosened epithelial structure and increased branching, as visualized by brightfield microscopy at day 1 and 2. Scale bars = 100 µm. (C) Ins1-eGFP mouse pancreatoids at day 4, day 5, day 6, day 7, and day 9, with the development of beta cells indicated by eGFP in green. Scale bars = 100 µm. Please click here to view a larger version of this figure.
Figure 3: Immunostaining of pancreatoids. (A) Immunostaining pancreatoid at day 5 to mark ducts by DBA in red, endocrine cells by Chga in green, and nuclei marked by DAPI in blue. (B) Immunostaining pancreatoid at day 7 to mark mesenchyme by Vimentin in red and pancreatic progenitors by Pdx1 in green. (B) Immunostaining pancreatoid at day 7 to mark beta cells by Insulin in red and pancreatic progenitors by Pdx1 in green. Please click here to view a larger version of this figure.
Figure 4: Transcript analysis. Quantitative PCR of day 7 pancreatoids for markers of progenitors and differentiating cells. Comparison to in vivo murine tissue is shown in Scavuzzo et al. (2017). Results are normalized to Gapdh. N = 2, scale bars are SEM. Please click here to view a larger version of this figure.
Component | Abbreviation | Final concentration |
Penicillin-Streptomycin | P/S | 1% |
FBS-free media supplement | 10% | |
Beta-Mercaptoethanol | bME | 0.1 mM |
Phorbol 12-Myristate 13-Acetate | PMA | 16 nM |
Y-27632 or ROCK inhibitor | RI | 10 uM |
Epidermal Growth Factor | EGF | 25 ng/mL |
R-Spondin1 | – | 500 ng/mL |
acidic Fibroblast growth factor, Fibroblast growth factor 1 | aFGF, FGF1 | 25 ug/mL |
Heparin sodium salt | Heparin | 2 U/mL |
Fibroblast growth factor 10 | FGF10 | 100 ng/mL |
Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 | DMEM/F12 | to 5 mL |
Table 1. Organogenesis media.
The progression of cell culture models is critical to properly model development, produce clinically relevant cell types, test drug efficacy, or even transplant to patients. However, artificially recapitulating development in a dish is challenging as we are still far from understanding the mechanisms of organogenesis and physiology in vivo. Thus in vitro cells are inefficiently generated, not fully functional, unable to be maintained for long periods of time, or harbor other abnormalities from comparable cells in the body. This is because many different cell types interact while complex morphogenetic changes occur to influence development and physiology. Gaining an understanding of how development proceeds by combining the convenience of in vitro systems while retaining the complexity of in vivo development would impart a valuable tool for the biomedical research.
The development of organoids is a promising avenue towards modeling the complexities of development. In this protocol, we outline how to make pancreatic organoids, termed pancreatoids, which retain native mesenchyme and robustly generate endocrine cells, albeit pancreatoids do not exhibit glucose responsiveness. This tool can be used to investigate mechanisms of development as well as functionality in a culture system that maintains the heterogeneity of tissue found in vivo. Further, this can be used for genetic screens or to screen small molecules or drugs. This is particularly interesting, as testing candidate drugs in relatively homogenous cell culture systems may circumvent effects of these compounds on other closely related cell types.
There are several critical steps during this protocol. First, the careful removal of embryos from the uterus is important as pulling the embryos out forcefully can rip the abdominal region and make it difficult to discern the gastrointestinal tract to obtain the pancreatic bud (step 1.3). Second, clean dissection of the pancreatic bud from the gastrointestinal tract is critical, as taking excess tissue may lead to differentiation of other cell types (step 1.4.4). To do this, it is important to pinch below the pancreatic bud and lift the overlaying tissue prior to isolating the pancreatic bud. Finally, when moving buds from the dispase back into the PBS to wash, it is imperative to use a borosilicate capillary tube and to not let the tissue touch the edge of the tube opening, otherwise, the tissue will stick to the tip of the tube (step 1.5.1). To avoid this, begin mouth pipetting solution before moving towards the bud, allowing the bud to go into the tube rather than on the outside.
This method permits the formation of endocrine cells in a 3D pancreatoid, however, the epithelial branching is more limited than other existing protocols16,17. Further, while insulin-producing endocrine cells form, they do not exhibit glucose responsiveness. Thus, further investigation into the maturation of these cells will provide valuable information both in the generation of functional pancreatoids as well as to the field of beta cell generation in general.
The generation of pancreatoids that develop endocrine cells, and, in the future, that obtain glucose responsiveness, has potential implications for the treatment of diabetes. Diabetes is a prime candidate for regenerative therapy, as pancreatic beta cells are lost or dysfunctional and replacing these cells can potentially alleviate disease complications. Progress has been made in differentiating hPSCs into beta cells, however, in diabetes, there are often dysfunctions to other cell types in the pancreas along with beta cells, including alpha cells or acinar cells28,29,30,31,32. Thus, generating new pancreatic tissue for transplantation can fully replace the afflicted tissue. With the additional investigation of murine pancreatoid formation and functioning, the developmental trajectory can be mimicked to generate human pancreatoids out of hPSCs. These human pancreatoids can be used for the personalized medicine to screen for responsiveness to drugs in a patient-specific context, and for regenerative therapy.
The authors have nothing to disclose.
We thank Jolanta Chmielowiec for helpful discussion regarding the protocol and manuscript. We also thank Benjamin Arenkiel for access to confocal microscope. This work was supported by the NIH (P30-DK079638 to M.B. and T32HL092332-13 to M.A.S. and M.B.), the McNair Medical Foundation (to M.B.), and the confocal core at the BCM Intellectual and Developmental Disabilities Research Center (NIH U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development).
2-Mercaptoethanol | Sigma-Aldrich | M6250 | |
Aspirator Tube Assemblies for Calibrated Microcapillary Pipettes | Sigma-Aldrich | A5177 | |
BarnStead NanoPure Nuclease-free water | ThermoFisher | D119 | |
Borosilicate Capillary Tubes | Sutter Instruments | GB1007515 | O.D. 1mm, I.D. 0.75mm, 1.5cm length |
CaCl2 | Sigma-Aldrich | C5080 | |
Cell-Repellent 96-Well Microplate | Greiner Bio-One | 650970 | U-bottom |
Centrifuge 5424 R | Eppendorf | 5401000013 | |
Chloroform | Sigma-Aldrich | 233306 | |
Chromogranin-A antibody | Abcam | ab15160 | |
Compact, Modular Stereo Microscope M60 | Leica | ||
Countess Automated Cell Counter | Invitrogen | C10310 | |
Countess Cell Counter Slides | Invitrogen | C10312 | |
CryoStar NX70 | ThermoFisher | 957000L | |
D-(+)-Glucose | Sigma-Aldrich | G7528 | |
DAPI (4',6-Diamidine-2'-phenylindole-dihydrochloride) | Roche | 10 236 276 001 | Powder |
DBA antibody | Vector Lab | RL-1032 | |
Dispase II, Powder | Gibco | 17105041 | |
DMEM/F-12, HEPES | Gibco | 11330032 | |
Dnase I | Invitrogen | 18068-015 | |
Dumont #5 Forceps | Fine Science Tools | 11251-10 | 0.05 x 0.02 mm; Titanium; Biology tip |
EGF (Epidermal growth factor) | Sigma-Aldrich | E9644 | |
Ethanol, 200 Proof | Decon Laboratories | 2716 | |
Forma Steri Cycle CO2 Incubators | ThermoFisher | 370 | |
Fluoromount-G | Southern Biotech | OB10001 | |
Heparin sodium salt from porcine intestinal mucosa | Sigma-Aldrich | H3149-10KU | |
INSM1 Antibody | Santa Cruz BioTechnology | sc-271408 | Polyclonal Mouse IgG |
Isopropanol | Fisher | a4164 | |
Isothesia Isoflurane, USP | Henry Schein | 11695-6776-2 | |
Insulin Antibody | Dako | A056401 | Polyclonal Guinea Pig |
KAPA SYBR FAST Universal | KAPA Biosystems | KK4618 | |
KCl | KaryoMax | 10575090 | |
KnockOut Serum Replacement | Invitrogen | 10828028 | |
Leica TCS SPE High-Resolution Spectral Confocal | Leica | ||
MgCl2 | Sigma-Aldrich | 442615 | |
Mouse C-Peptide ELISA | ALPCO | 80-CPTMS-E01 | |
Mouse Ultrasensitive Insulin ELISA | ALPCO | 80-INSMSU-E01 | |
MX35 Microtome Blades | ThermoFisher | 3052835 | |
NaCl | Sigma-Aldrich | S7653 | |
NaHCO3 | Sigma-Aldrich | S3817 | |
NaH2PO4 | Sigma-Aldrich | ||
Normal Donkey Serum | Jackson Immuno Research | 017-000-121 | |
Paraformaldehyde | Sigma-Aldrich | 158127 | |
PBS 1X | Corning | 21-040-CV | |
Pdx1 antibody | DSHB | F6A11 | Monoclonal Mouse MIgG1 |
Peel-A-Way Disposable Embedding Molds | VWR | 15160-157 | |
Penicillin-Streptomycin Solution | Corning | MT30002CI | |
PMA (Phorbol 12-Myristate 13-Acetate) | Sigma-Aldrich | P1585 | |
Protein LoBind Microcentrifuge Tubes | Eppendorf | 22431081 | 1.5mL Capacity |
Recombinant Human FGF-10 Protein | R&D Systems | 345-FG | |
Recombinant Human FGF-Acidic | Peprotech | 100-17A | |
Recombinant Human R-Spondin I Protein | R&D Systems | 4546-RS | |
BenchRocker 2D | Benchmark | BR2000 | |
Sucrose 500g | Sigma-Aldrich | S0389 | |
SuperFrost Plus Microscope Slides | Fisher Scientific | 12-550-15 | |
Super Pap Pen | Electron Microscopy Sciences | 71310 | |
Thermomixer R | Eppendorf | 05-412-401 | |
Tissue Tek O.C.T. Compound | Sakura | 4583 | |
Triton X-100 | Sigma-Aldrich | T8787 | |
TRIzol Reagent | Invitrogen | 15596018 | |
TrypLE Express | Invitrogen | 12604039 | (1x), no Phenol Red |
Trypan Blue Stain | Invitrogen | 15250061 | For cell counting slides |
Trypsin-EDTA (0.05%) | Corning | 25-052-CI | |
Trypsin-EDTA (0.25%) | Gibco | 25200072 | Phenol Red |
Ultra-Low Attachment 24-Well Plate | Corning | 3473 | |
Ultra-Low Attachment Spheroid Plate 96-Well | Corning | 4520 | |
Vimentin Antibody | EMD Millipore | AB5733 | Polyclonal Chicken IgY |
Vortex Genie | BioExpres | S-7350-1 | |
Y-27632 Dihydrochloride | R&D Systems | 1254 | Also known as ROCK inhibitor |
Zeiss 710 Confocal Microscope | Zeiss |